InspireMD reports Q4 EPS (19c) vs (16c) last year

Reports Q4 revenue $1.9M vs $1.76M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “2024 was a year of tremendous progress at InspireMD. We advanced CGuard Prime, our best-in-class carotid implant, toward potential U.S. approval by submitting our PMA application to the FDA. We also initiated the CGUARDIANS II pivotal study for its use in the large and growing TCAR market – an important step in expanding our development pipeline.”